Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- Japan Will Receive MFN Status on US Drug Tariffs: Akazawa
October 1, 2025
- MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
October 1, 2025
- Takeda’s Oveporexton Gets Sakigake Tag for Narcolepsy Type 1
September 30, 2025
- Japan Hands Out Orphan Tags to 10 Compounds
September 30, 2025
- Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
- Panel Flags Concern over Drug-Only Focus in Proposed Cost-Cuts for 2026 Reform
September 29, 2025
- US Confirms 50% Tariffs on Japan’s Heavy Trucks; Pharma Capped at 15%
September 29, 2025
- Japan to Set Criteria for “Challenge Applications” in Medical Device Pricing Reform
September 29, 2025
- Japan Says It’s Too Early to Gauge Impact of US Pharma Tariffs
September 29, 2025
- Pharma Support Needed to Bridge Biotech’s “Valley of Death”: Council Member
September 26, 2025
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- LDP Leadership Race Underway, Healthcare-Savvy Lawmakers Among Endorsers
September 24, 2025
- FPMAJ Calls for Scrapping Huge-Seller, Spillover Re-Pricing at Public-Private WG Hearing
September 24, 2025
- Japan OKs Biosimilars of Eylea, Actemra, Simponi, Ranmark in Likely First Debut
September 22, 2025
- MHLW Panel Endorses Rx-to-OTC Switch of Tadalafil in Japan
September 22, 2025
- Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster
September 22, 2025
- Amitiza, Shingrix under PMDA Safety Review
September 22, 2025
- Japan Extends Re-Examination Period for Nurtec, Dormicum
September 22, 2025
- Takaichi Highlights Drug Discovery as Crucial Growth Field in LDP Race
September 22, 2025
- Hayashi Stresses Drug Discovery as Key Growth Field in LDP Race
September 19, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…